We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00966953
Recruitment Status : Completed
First Posted : August 27, 2009
Results First Posted : August 27, 2009
Last Update Posted : September 22, 2009
Information provided by:

Study Description
Brief Summary:
Clinical research study to determine the anti-plaque efficacy of prototype dentifrices via a 4-day brushing regiment

Condition or disease Intervention/treatment Phase
Gingival Diseases Drug: Fluoride Drug: Triclosan/Fluoride toothpaste Other: antibacterial plant extract Phase 3

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing.
Study Start Date : October 2007
Primary Completion Date : January 2008
Study Completion Date : January 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Gum Disease
Drug Information available for: Triclosan
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Placebo Comparator: Fluoride Toothpaste
fluoride control
Drug: Fluoride
Brush twice daily
Active Comparator: Total/Whitening
positive control
Drug: Triclosan/Fluoride toothpaste
Brush twice daily
Experimental: antibacterial plant extract 1
Drug: Fluoride
Brush twice daily
Other Name: honokiol
Experimental: antibacterial plant extract 2
Drug: Fluoride
Brush twice daily
Other: antibacterial plant extract
Brush twice daily
Other Name: Honokiol

Outcome Measures

Primary Outcome Measures :
  1. Plaque Index [ Time Frame: 8 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male or female volunteers 18-65 years of age.
  • Good general health.
  • Must sign informed consent form.
  • Must discontinue oral hygiene on the mornings of each appointment and between sampling periods.
  • No history of allergy to personal care consumer products, or their ingredients, relevant to any ingredient in the test products as determined by the dental/medical professional monitoring the study.

Exclusion Criteria:

  • Medical condition which requires pre-medication prior to dental procedures/visits.
  • Medical condition which precludes eating/drinking for 12 hrs.
  • History of allergy to common dentifrice ingredients.
  • Subjects unable or unwilling to sign the informed consent form.
  • Moderate or advanced periodontal disease.
  • Two or more decayed untreated dental sites at screening.
  • Other disease of the hard or soft oral tissues.
  • Impaired salivary function (e.g. Sjogren's syndrome or head and neck irradiation).
  • Use of medications that can currently affect salivary flow.
  • Current use of antibiotics.
  • Use of antibiotics or antimicrobial drugs within 30 days prior to study visit #1.
  • Pregnant or nursing women.
  • Participation in any other clinical study within 30 days prior to enrollment into this study.
  • Use of tobacco products.
  • Subjects who must receive dental treatment during the study dates.
  • Current use of Antibiotics for any purpose.
  • Immune compromised individuals (HIV,AIDS, immuno suppressive drug therapy).
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00966953

United States, New York
Eastman Dental Center - University of Rochester
Rochester, New York, United States, 14642-8315
Sponsors and Collaborators
Colgate Palmolive
Principal Investigator: Yanfang Ren, DDS
More Information

Responsible Party: William DeVizio/VP - Clinical Research, Colgate Palmolive
ClinicalTrials.gov Identifier: NCT00966953     History of Changes
Other Study ID Numbers: ERO-0907-PLA-16-RR
First Posted: August 27, 2009    Key Record Dates
Results First Posted: August 27, 2009
Last Update Posted: September 22, 2009
Last Verified: September 2009

Additional relevant MeSH terms:
Gingival Diseases
Periodontal Diseases
Mouth Diseases
Stomatognathic Diseases
Anti-Bacterial Agents
Cariostatic Agents
Protective Agents
Physiological Effects of Drugs
Anti-Infective Agents
Anti-Infective Agents, Local
Fatty Acid Synthesis Inhibitors
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Anti-Arrhythmia Agents
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Central Nervous System Depressants
Enzyme Inhibitors
Gastrointestinal Agents
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
Anti-Allergic Agents